ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-02 08:30 |
Abivax publie ses résultats annuels 2023 et présente un point d’avancement sur …
|
French | 307.3 KB | ||
| 2024-04-02 08:30 |
Abivax reports 2023 financial results and operational update
|
English | 44.3 KB | ||
| 2024-03-27 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 91.0 KB | ||
| 2024-02-23 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 90.7 KB | ||
| 2024-02-13 08:30 |
Abivax annonce la présentation de quatre abstracts sur obefazimod dans la recto…
|
French | 141.0 KB | ||
| 2024-02-13 08:30 |
Abivax announces presentation of four abstracts for obefazimod in ulcerative co…
|
English | 16.3 KB | ||
| 2024-02-07 08:30 |
Abivax: Ana Sharma est nommée Vice-Présidente,Global Head of Quality d’Abivax
|
French | 113.3 KB | ||
| 2024-02-07 08:30 |
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
|
English | 9.8 KB | ||
| 2024-02-02 08:30 |
Abivax annonce une mise à jour de son programme de développement clinique de ph…
|
French | 120.4 KB | ||
| 2024-02-02 08:30 |
Abivax announces update to obefazimod Phase 2b clinical development program in …
|
English | 10.5 KB | ||
| 2024-01-29 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 91.6 KB | ||
| 2024-01-29 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2023.
|
French | 164.6 KB | ||
| 2024-01-24 08:30 |
Abivax organise le 6 février 2024 un événement investisseurs avec des experts q…
|
French | 100.8 KB | ||
| 2024-01-24 08:30 |
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 …
|
English | 7.3 KB | ||
| 2024-01-22 08:30 |
Abivax: Perspectives stratégiques d’Abivax pour 2024 et principales étapes au c…
|
French | 192.7 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
